Lilly’s big step into radiopharma comes via $1.4B Point takeout

Lilly’s $1.4 billion acquisition of Point gives the pharma a radiopharma platform and a manufacturing center close to its own headquarters, and comes ahead of a key readout that could have driven up the biotech’s price.

While Point Biopharma Global Inc. (NASDAQ:PNT) has already partnered its two most advanced programs with Lantheus Holdings Inc. (NASDAQ:LNTH), the radioligand company still could post a substantial gain in value if a Phase III study of lead molecule PNT2002 reads out positively this quarter...